BSW Wealth Partners Acquires 369 Shares of Novo Nordisk A/S (NYSE:NVO)

BSW Wealth Partners lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 4.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,083 shares of the company’s stock after purchasing an additional 369 shares during the quarter. BSW Wealth Partners’ holdings in Novo Nordisk A/S were worth $1,082,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NVO. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Independence Bank of Kentucky lifted its stake in Novo Nordisk A/S by 192.7% in the 3rd quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock valued at $1,368,000 after purchasing an additional 7,565 shares during the last quarter. Traynor Capital Management Inc. grew its holdings in Novo Nordisk A/S by 3.4% during the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock worth $36,364,000 after purchasing an additional 10,019 shares during the period. Cetera Investment Advisers raised its stake in Novo Nordisk A/S by 453.3% in the first quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after buying an additional 217,545 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $1,624,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, October 10th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $0.01 during mid-day trading on Friday, reaching $111.94. 4,554,729 shares of the company’s stock were exchanged, compared to its average volume of 4,701,665. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The business’s fifty day simple moving average is $124.25 and its two-hundred day simple moving average is $130.90. The firm has a market capitalization of $502.33 billion, a PE ratio of 38.34, a price-to-earnings-growth ratio of 1.46 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is currently 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.